6 papers in the library · 95 citations · publishing 2016-2026
EBioMedicine August 1, 2026
The use of psilocybin for treatment-resistant depression (TRD) is moving towards clinical use, and two unresolved questions will shape what comes next: how large and durable the benefit is, and what produces it? The strongest peer-reviewed efficacy signal is a phase 2b trial, in which one dose of synthetic psilocybin with psychological support approximately doubled the depression-score...
EBioMedicine December 1, 2025 Kiranpreet Gill, Angharad N De Cates, Chantelle Wiseman et al.
Depression remains a global public health challenge, prompting interest in translational targets which allow for more effective and rapidly acting interventions. Nitrous oxide (N2O), an N-methyl-d-aspartate receptor antagonist, has demonstrated potential as a rapid-acting antidepressant. This study synthesised existing data on the efficacy and safety of N2O in depressive disorders. We...
EBioMedicine March 26, 2024 Allen Ting Chun Lee, Yishan Luo, Zhaohua Huo et al. 7 citations
Summary: Background: Having more cognitive activities may prevent dementia, but its evidence of modulating the functional brain network is limited. This randomised controlled trial (RCT) investigated the effect of increased cognitive activity participation on the default mode network (DMN) in older adults who had already been having regular cognitive activity participation and experiencing...
EBioMedicine May 13, 2022 Ting Xue, Benjamin Chiao, Tianjiao Xu et al.
Summary Background There have been mixed reports on the beneficial effects of meditation in cardiovascular disease (CVD), which is widely considered the leading cause of death worldwide. Methods To clarify the role of meditation in modulating the heart-brain axis, we implemented an extreme phenotype strategy, i.e., Tibetan monks (BMI > 30) who practised 19.20 ± 7.82 years of meditation on...
EBioMedicine September 1, 2016 David Martin, Charles D. Nichols 88 citations
There has recently been a resurgence of interest in psychedelics, substances that profoundly alter perception and cognition and have recently demonstrated therapeutic efficacy to treat anxiety, depression, and addiction in the clinic. The receptor mechanisms that drive their molecular and behavioral effects involve activation of cortical serotonin 5-HT 2A receptors, but the responses of...
EBioMedicine August 1, 2016 Erica Sibinga
In this issue of EBioMedicine, Shao et al. (2016-in this issue) make a significant and interesting contribution to a growing literature of changes seen in participants who receive formal programmatic instruction in mindfulness meditation. Since Kabat-Zinn's (1982) paper reporting on what would become the mindfulness-based stress reduction (MBSR) program, the literature and application of...